Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sionna TherapeuticsSION +0.51%12 EV-to-OCF is -0.86 as of Aug. 18, 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Sionna Therapeutics ranks worse than 65.58% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sionna Therapeutics's Enterprise Value is $65.60 Mil.
Sionna Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-75.92 Mil. Therefore, Sionna Therapeutics's EV-to-OCF for today is -0.86.
The historical rank and industry rank for Sionna Therapeutics's EV-to-OCF or its related term are showing as below:
SION'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.87 Med: 0 Max: -0.69
Current: -0.86
During the past 4 years, the highest EV-to-OCF of Sionna Therapeutics was -0.69. The lowest was -0.87. And the median was .
SION's EV-to-OCF is ranked worse than 65.58% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs SION: -0.86
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sionna Therapeutics's PE Ratio (TTM) for today is calculated as:
Sionna Therapeutics's share price for today is $5.94.
Sionna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sionna Therapeutics EV-to-OCF Related Terms
Sionna Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sionna Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sionna Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sionna Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sionna Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sionna Therapeutics's EV-to-OCF falls into.
Sionna Therapeutics's current Enterprise Value is $65.60 Mil.
Sionna Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sionna Therapeutics (SION) has a EV-to-OCF of -0.86 as of Aug. 18, 2026. According to the industry distribution chart, Sionna Therapeutics ranks #924 out of 1409 companies in the Biotechnology industry, placing it in the top 65.6%.
Is Sionna Therapeutics' EV-to-OCF too high?
Sionna Therapeutics' current EV-to-OCF is -0.86. Based on the distribution chart, Sionna Therapeutics ranks #924 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' EV-to-OCF compare to HRMY and VRDN?
According to the Biotechnology industry distribution chart, Sionna Therapeutics ranks #924 out of 1409 companies for EV-to-OCF. This places Sionna Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sionna Therapeutics's current EV-to-OCF is -0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current EV-to-OCF of -0.86. The current EV-to-OCF is -0.86. Sionna Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current EV-to-OCF is -0.86 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score
Get the complete analysis for SION
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SION has been successfully added to your 
